Assistant Professor of Medicine, Dana-Farber Cancer Institute
Oncology
Dr. Rameen Beroukhim, MD
|
|
Give Review
Rameen Beroukhim is an expert in the field of Oncology. He attended University of California San Francisco School of Medicine. University of California San Francisco School of Medicine is one of the top medical schools in the US. University of California San Francisco School of Medicine has a rank of 3 in research and a 3 in primary care He received awards:"Regional Top Doctor". Rameen Beroukhim is also a published physician. He has 40 publication published. The most recent publication is: Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.
Publications
- Expression profiles of 151 pediatric low-grade Gliomas reveal molecular differences associated with location and histological subtype.
- Exome sequencing of lymphomas from three dog breeds reveals somatic mutation patterns reflecting genetic background.
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.
- Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma.
- Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
- Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.
- An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma.
- SGK3 Mediates INPP4B-Dependent PI3K Signaling in Breast Cancer.
- Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage Gliomas.
- Beating the odds: extreme long-term survival with glioblastoma.
- Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage.
- Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition.
- Retrospective study of using carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.
- Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma.
- Pan-Cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins.
- Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: A gene expression imaging study.
- Pediatric low-grade Gliomas: How modern biology reshapes the clinical field.
- Long-term outcome of 4,040 children diagnosed with pediatric low-grade Gliomas: An analysis of the Surveillance Epidemiology and End Results (SEER) database.
- In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian Cancer oncogene.
- SQSTM1 Is a Pathogenic Target of 5q Copy Number Gains in Kidney Cancer.
- The Somatic Genomic Landscape of Glioblastoma.
- The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor.
- Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.
- The Cancer Genome Atlas Pan-Cancer analysis project.
- Pan-Cancer patterns of somatic copy number alteration.
- Genomic analysis of diffuse pediatric low-grade Gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1.
- Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
- Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.
- ATARiS: Computational quantification of gene suppression phenotypes from multisample RNAi screens.
- Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.
- Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma.
- Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of Genome Instability and Oncogenesis.
- Interpreting cancer genomes using Systematic host network perturbations by tumour virus proteins.
- Recurrent hemizygous deletions in Cancers may optimize proliferative potential.
- Sequence analysis of mutations and translocations across breast Cancer subtypes.
- Absolute quantification of somatic DNA alterations in human Cancer.
- Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency.
- Somatic Activation of AKT3 Causes Hemispheric Developmental Brain Malformations.
- A prognostic cytogenetic scoring System to guide the adjuvant management of patients with atypical meningioma.
Schools
University Of Californiasan Franciscoschool Of Med
University Of Ca San Francisco
Conditions Treated
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- Lung Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
Brigham and Women's Hospital -
UCSF -
University of California San Francisco School of Medicine
Hospital
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Dana-Farber Cancer Institute
Helpful Reviews
Similar Doctors
|
|
Dr. Daniel A. Haber, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Kerry E. Kilbridge, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel G. Tenen, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Hao Zhu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Channing Yu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lowell E. Schnipper, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Beverly Moy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David Barbie, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Douglas A. Rubinson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert E. Martell, MD
This Doctor is OpenDoctor Recommended.
|